Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk

Circulation

Volumn 117, Issue 22, 2008, Pages 2875-2883

  Greving, Jacoba P ^a   Buskens, Erik ^a,c   Koffijberg, Hendrik ^a   Algra, Ale ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Aspirin; Cardiovascular diseases; Cost benefit analysis; Markov chains; Primary prevention

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

AGE FACTORS; AGED; ASPIRIN; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DRUG EVALUATION; FEMALE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MONTE CARLO METHOD; PRIMARY PREVENTION; RISK ASSESSMENT; SEX FACTORS;

EID: 44649193108     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.735340     Document Type: Article

References (45)

1. Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
2. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 2001;85:265-271.
3. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:161-172.
4. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003;163:2006-2010.
5. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306-313.
6. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study, 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
7. Augustovski FA, Cantor SB, Thach CT, Spann SJ. Aspirin for primary prevention of cardiovascular events. J Gen Intern Med. 1998;13:824-835.
8. Nelson MR, Liew D, Bertram M, Vos T. Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or = 70. BMJ. 2005;330:1306.
9. Lamotte M, Annemans L, Evers T, Kubin M. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. Pharmacoeconomics. 2006;24:155-169.
10. Marshall T. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study. Eur J Cardiovasc Prev Rehabil. 2006;13:523-528.
11. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006;144:326-336.
12. Annemans L, Lamotte M, Kubin M, Evers T, Verheugt FW. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation. Int J Clin Pract. 2006;60:1129-1137.
13. Franco OH, der Kinderen AJ, De Laet C, Peeters A, Bonneux L. Primary prevention of cardiovascular disease: cost-effectiveness comparison. Int J Technol Assess Health Care. 2007;23:71-79.
14. Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Aspirin for the primary prevention of cardiovascular disease in women. Arch Intern Med. 2007;167:290-295.
15. Tsutani K, Igarashi A, Fujikawa K, Evers T, Kubin M, Lamotte M, Annemans L. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan. Intern Med. 2007;46:157-162.
16. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338.
17. Koek HL, de Bruin A, Gast A, Gevers E, Kardaun JW, Reitsma JB, Grobbee DE, Bots ML. Incidence of first acute myocardial infarction in the Netherlands. Neth J Med. 2007;65:434-441.
18. Jager-Geurts MH, Peters RJ, van Dis SJ, Bots ML. Cardiovascular diseases in the Netherlands 2006: figures on risk factors, morbidity and mortality. The Hague, The Netherlands: Netherlands Heart Foundation; 2006. Available at: http://www.hartstichting.nl. Accessed August 20, 2007.
19. van Leerdam ME, Vreeburg EM, Rauws EA, Geraedts AA, Tijssen JG, Reitsma JB, Tytgat GN. Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol. 2003;98:1494-1499.
20. Rockall TA, Logan RF, Devlin HB, Northfield TC. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom: Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ. 1995;311:222-226.
21. Koek HL, de Bruin A, Gast F, Gevers E, Kardaun JW, Reitsma JB, Grobbee DE, Bots ML. Short- and long-term prognosis after acute myocardial infarction in men versus women. Am J Cardiol. 2006;98:993-999.
22. Statistics Netherlands (CBS). Lifetables Dutch population by age and sex, 1996-2000. Voorburg/Heerlen, the Netherlands: Statistics Netherlands; 2002. Available at: http://statline.cbs.nl. Accessed March 16, 2006.
23. Brønnum-Hansen H, Davidsen M, Thorvaldsen P. Long-term survival and causes of death after stroke. Stroke. 2001;32:2131-2136.
24. Fogelholm R, Murros K, Rissanen A, Avikainen S. Long term survival after primary intracerebral haemorrhage: a retrospective population based study. J Neurol Neurosurg Psychiatry. 2005;76:1534-1538.
25. Brønnum-Hansen H, Jørgensen T, Davidsen M, Madsen M, Osler M, Gerdes LU, Schroll M. Survival and cause of death after myocardial infarction: the Danish MONICA study. J Clin Epidemiol. 2001;54:1244-1250.
26. Bergman L, van der Meulen JH, Limburg M, Habbema JD. Costs of medical care after first-ever stroke in the Netherlands. Stroke. 1995;26:1830-1836.
27. Wolfe CD. The impact of stroke. Br Med Bull. 2000;56:275-286.
28. Tsevat J, Goldman L, Soukup JR, Lamas GA, Connors KF, Chapin CC, Lee TH. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993;13:161-165.
29. Naglie IG, Detsky AS. Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision analysis. Med Decis Making. 1992;12:239-249.
30. Post PN, Stiggelbout AM, Wakker PP. The utility of health states after stroke: a systematic review of the literature. Stroke. 2001;32:1425-1429.
31. Torrance GW, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care programs. Health Serv Res. 1972;7:118-133.
32. Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2006;98:746-750.
33. Hennekes CH, Sacks FM, Tonkin A, Jukema JW, Byington RP, Pitt B, Berry DA, Berry SM, Ford NF, Walker AJ, Natarajan K, Sheng-Lin C, Fiedorek FT, Belder R. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. Arch Intern Med. 2004;164:40-44.
34. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G. Methods for the Economic Evaluation of Health Care Programmes. New York, NY: Oxford University Press Inc; 2005.
35. van Loenen A. Pharmacotherapeutic Compass 2005. Amstelveen, the Netherlands: Health Care Insurance Board; 2005.
36. Oostenbrink JB, Bouwmans CA, Koopmanschap MA, Rutten FF. Instructions for Cost Assessment, Methods and Directive of Prices for Economic Evaluation in Health Care [in Dutch]. Amstelveen, the Netherlands: Health Care Insurance Board; 2004.
37. de Boer MJ, van Hout BA, Liem AL, Suryapranata H, Hoorntje JC, Zijlstra F. A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction. Am J Cardiol. 1995;76:830-833.
38. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease: Scandinavian Simvastatin Survival Study Group. N Engl J Med. 1997;336:332-336.
39. Buskens E, Nederkoorn PJ, Buijs-van der Woude T, Mali WP, Kappelle LJ, Eikelboom BC, van der Graaf Y, Hunink MG. Imaging of carotid arteries in symptomatic patients: cost-effectiveness of diagnostic strategies. Radiology. 2004;233:101-112.
40. van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/Eratios alongside a clinical trial. Health Econ. 1994;3:309-319.
41. Sensible and Sustainable Care. Zoetermeer, the Netherlands; Council for Public Health and Health Care: 2006.
42. Ridker PM, Cook NR, Buring JE. Use of aspirin as primary prevention of cardiovascular events. JAMA. 2006;296:391-392.
43. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293-298.
44. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetière P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM, for the SCORE Project Group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.
45. Christie B. Guidelines on treating risk factors turn healthy people into patients, doctors say. BMJ. 2006;333:988.